NanoBio Corporation
P.O. Box 8110
Ann Arbor
Michigan
48107
United States
Tel: 734-302-4000
Fax: 734-302-6150
Website: http://www.nanobio.com/
Email: marketing@nanobio.com
83 articles about NanoBio Corporation
-
Pharnext: David Stout joins Pharnext's Board of Directors
9/17/2018
Pharnext SA announced the cooptation of David Stout as an independent Director of Pharnext.
-
NanoBio Announces Corporate Name Change to BlueWillow Biologics and Closes $10M Series A Financing
5/7/2018
Move Reflects Focus on Advancing Several Intranasal Vaccines to Human Studies
-
NanoBio Corporation And Porton Biopharma Receive Approval To Advance Next Generation Anthrax Vaccine
6/19/2017
-
NanoBio Corporation Receives SBIR Grant For Genital Herpes Vaccine
3/6/2017
-
NanoBio Corporation Awarded U.S. Patent For RSV Vaccine
12/19/2016
-
NanoBio Corporation To Present Intranasal Pertussis Vaccine Data At The Mucosal Immunology Course & Symposium Meeting
7/27/2016
-
NanoBio Corporation's Chlamydia Vaccine Improves Clearance Of Bacteria And Prevents Pelvic Inflammatory Disease In Mice
12/2/2015
-
NanoBio Corporation's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine
9/23/2015
-
NanoBio CorporationTo Present Data Demonstrating The Potential For Its Intranasal Vaccine To Protect Against Genital Herpes Infection
10/8/2014
-
NanoBio Corporation's Intranasal Vaccine Demonstrates Robust Protection Against Herpes Simplex-2 Infection
4/28/2014
-
Merck & Co., Inc. Licenses NanoBio Corporation Technology
3/27/2014
-
NanoBio Corporation Awarded Up to $10 Million in National Institutes of Health (NIH) Funding to Develop a Pandemic Influenza Vaccine
10/29/2013
-
NanoBio Corporation; Interscience Conference on Antimicrobial Agents and Chemotherapy
9/11/2013
-
NanoBio Corporation Closes $11 Million Series C Financing
11/28/2012
-
NanoBio Corporation Announces Data Presentation on Its Nanoemulsion Adjuvanted RSV Vaccine at IDWeek 2012
10/15/2012
-
NanoBio Corporation Promotes David Peralta to Chief Executive Officer
10/9/2012
-
NanoBio Corporation to Report Data on its Nanoemulsion Adjuvanted Intranasal RSV Vaccine at the 8th Annual International Respiratory Syncytial Virus Symposium
9/24/2012
-
NanoBio Corporation to Present Preclinical Data on its Nanoemulsion Adjuvanted Intranasal RSV Vaccine and Novel Inhaled Cystic Fibrosis Therapy at 52nd Annual ICAAC Meeting
9/10/2012
-
NanoBio Corporation to Collaborate in Research Effort for Respiratory Syncytial Virus Vaccine With Merck & Co., Inc.
12/8/2011
-
NanoBio Corporation Secures Novel Antigen Source Through National Institutes of Health (NIH) for its Intranasal RSV Vaccine
8/3/2011